caa a22 4500 469118784 CHVBK 20180323133132.0 cr unu---uuuuu 170328e19921201xx s 000 0 eng 10.1007/BF02247727 doi (NATIONALLICENCE)springer-10.1007/BF02247727 D1/D2 dopamine and N-methyl- d -aspartate (NMDA) receptor participation in experimental catalepsy in rats [Elektronische Daten] [Anita Verma, S. Kulkarni] Mixed D1/D2 dopamine (DA) antagonists, perphenazine (5 mg/kg) and haloperidol (2 mg/kg) induced catalepsy in rats. SCH 23390 (1 mg/kg), a D1 DA antagonist, also produced catalepsy. Co-administration of perphenazine (0.5 mg/kg) and SCH 23390 (0.1 mg/kg), at low doses, produced a marked increase in cataleptic response. B-HT 920, a D2 agonist, reversed the cataleptogenic effects of perphenazine, haloperidol and SCH 23390. SKF 38893 (5 mg/kg) reduced the cataleptogenic effect of SCH 23390 but failed to reverse haloperidol- or perphenazine-induced catalepsy. SKF 38393 (10 mg/kg), however, protected the animals against perphenazine- induced catalepsy. Combined administration of B-HT 920 (0.1 mg/kg) and SKF 38393 (5 mg/kg) enhanced the protective effect of B-HT 920 in SCH 23390-treated animals but not in animals treated with haloperidol or perphenazine. MK-801 (0.025-0.5 mg/kg), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, reduced the cataleptogenic effects of perphenazine, haloperidol as well as SCH 23390. The anticataleptic action of MK-801 was enhanced by scopolamine (0.1 mg/kg) but not by bromocriptine (1 mg/kg) or clonidine (0.05 mg/kg) in perphenazine-treated rats. Unlike B-HT 920 (0.1 mg/kg), SKF 38393 (5 mg/kg) potentiated the anticataleptic effect of MK-801 (0.01 mg/kg) against SCH 23390-induced catalepsy. The above data suggests D1/D2 interdependence in catalepsy and a modulatory role of D1 and D2 DA receptor stimulation on the anticataleptic effect of MK-801. Springer-Verlag, 1992 Catalepsy nationallicence D1 receptor nationallicence D2 receptor nationallicence Perphenazine nationallicence Haloperidol nationallicence SCH 23390 nationallicence MK-801 nationallicence Verma Anita Pharmacology Division, Department of Pharmaceutical Sciences, Panjab University, 160014, Chandigarh, India aut Kulkarni S. Pharmacology Division, Department of Pharmaceutical Sciences, Panjab University, 160014, Chandigarh, India aut Psychopharmacology Springer-Verlag 109/4(1992-12-01), 477-483 0033-3158 109:4<477 1992 109 213 https://doi.org/10.1007/BF02247727 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02247727 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Verma Anita Pharmacology Division, Department of Pharmaceutical Sciences, Panjab University, 160014, Chandigarh, India aut NATIONALLICENCE 700 1- Kulkarni S. Pharmacology Division, Department of Pharmaceutical Sciences, Panjab University, 160014, Chandigarh, India aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 109/4(1992-12-01), 477-483 0033-3158 109:4<477 1992 109 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer